We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

By HospiMedica International staff writers
Posted on 01 May 2024
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately 99,000 deaths each year. Pathogens on surfaces can survive for days to months, and studies indicate that 50% of surfaces in healthcare settings are not adequately disinfected during manual cleaning processes. The financial burden of HAIs on the U.S. healthcare system is estimated to be between USD 28 billion to USD 33 billion annually. Now, the results of an in-hospital disinfection study involving the use of novel handheld Filtered Far UV-C devices have demonstrated their effectiveness in quickly reducing HAI-causing pathogens on high-touch clinical surfaces, addressing a significant challenge in hospital settings where traditional manual disinfection methods often fall short.

The research, conducted at The University of Texas MD Anderson Cancer Center (Houston, TX, USA), utilized handheld Filtered Far UV-C devices provided by Freestyle Partners (Detroit, MI, USA). The study showed a significant reduction in surface pathogens that cause HAIs within the clinical areas of hematologic malignancy and stem cell units. Filtered Far UV-C, a safe form of disinfection technology, uses invisible germicidal light that kills viruses, bacteria, spores, and fungi almost instantly, eliminating the need for the 2–10-minute dwell times required by chemical disinfectants. These devices offer a no-touch disinfection solution, particularly advantageous where manual cleaning is not feasible. This study further confirms the efficacy and speed of these devices in reducing dangerous pathogens on high-touch surfaces, thanks to their patented technology that ensures proper usage and achieves desired disinfection results.

“This study provides further real-world data on the efficacy of handheld Filtered Far UV-C devices to reduce surface pathogens which we hope could ultimately improve patient care and tackle the tremendous expenses healthcare institutions face in fighting HAIs,” said Jennifer Rosen, co-founder of Freestyle Partners, LLC.

Related Links:
The University of Texas MD Anderson Cancer Center
Freestyle Partners

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Hemostatic Agent
HEMOBLAST Bellows

Channels

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more